ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Pregabalin fares poorly for Fibromyalgia outside of US
Monday 10 October 2011
Researchers looked at the effectiveness of pregabalin - the drug in Lyrica - outside of the U.S. They enrolled 747 fibromyalgia patients from medical facilities in multiple countries and tested 3 different dosages -- 300, 450 and 600 mg a day for 14 weeks. They were looking for changes in pain, sleep and function.
Initially, pain went down in all the treatment groups, and sleep appeared to improve across the board. However, by the end of the study researchers concluded that 300 and 600-mg doses didn't provide consistent benefits. The 450-mg dose showed only a modest effect in pain and function.
To me, this study raises a couple of questions, especially since typical Lyrica dosages in the U.S. are 300 and 450:
At this moment, there's no way to answer either of these questions - we simply don't have enough information. However, I think these are both valid questions for researchers to pursue.
The Importance of Subgrouping
Many top fibromyalgia researchers have talked about the need for accurate subgrouping, but so far we haven't seen a lot of research into it. Some experts believe this condition can be broken down into several subgroups that actually represent different illnesses that need to be researched and treated differently from each other.
If they're right, current studies are significantly flawed, which could be why they haven't uncovered treatments that are effective for large percentages of us - one treatment, for example, might only be effective for 2 or 3 subgroups, but 6 subgroups could be represented in the study.
If subgroups vary geographically, as the pregabalin study may suggest, it could help reveal some of the causal factors. Differences in diet, pollutants, common infectious agents and more could be better identified if we could tie subgroups to regions.
I believe that we won't make a lot of progress on treatment or causation until researchers clearly identify subgroups and start studying them independently. Until then, we'll be left with the current process of guessing, experimenting and hoping.
Learn more or join the conversation!
The above, with comments, originally appeared here.
blog comments powered by Disqus